SKF 106610

Drug Profile

SKF 106610

Latest Information Update: 01 Oct 1998

Price : $50

At a glance

  • Originator AnorMED
  • Class Antirheumatics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetes mellitus; Inflammation

Most Recent Events

  • 01 Oct 1998 Discontinued-Preclinical for Diabetes mellitus in USA (Unknown route)
  • 01 Oct 1998 Discontinued-Preclinical for Inflammation in USA (Unknown route)
  • 05 Aug 1998 A preclinical study has been added to the Inflammation pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top